Display options
Cite
Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12:21doi: 10.1186/1472-6890-12-21.
Le Rhun, E., Massin, F., Tu, Q., Bonneterre, J., Bittencourt, M. d. e. . C., & Faure, G. C. (2012). Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC clinical pathology, 1221. https://doi.org/10.1186/1472-6890-12-21
Le Rhun, Emilie, et al. "Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis." BMC clinical pathology vol. 12 (2012): 21. doi: https://doi.org/10.1186/1472-6890-12-21
Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt Mde C, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012 Nov 12;12:21. doi: 10.1186/1472-6890-12-21. PMID: 23145812; PMCID: PMC3539901.
Copy Download .nbib Format: NLM
Share it on

BMC Clin Pathol. 2012 Nov 12;12:21. doi: 10.1186/1472-6890-12-21.

Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis.

BMC clinical pathology

Emilie Le Rhun, Frédéric Massin, Qian Tu, Jacques Bonneterre, Marcelo De Carvalho Bittencourt, Gilbert C Faure

Affiliations

  1. Neurology, Breast Unit, Deparment of Medical Oncology, Oscar Lambret Center, Lille, France and Neuro-oncology, University Hospital, Lille, France. [email protected].

PMID: 23145812 PMCID: PMC3539901 DOI: 10.1186/1472-6890-12-21

Abstract

BACKGROUND: The diagnosis of leptomeningeal metastasis (LM) in patients with solid tumors remains difficult. The usual diagnostic methods of cytomorphological assessment of cerebro-spinal fluid (CSF) and gadolinium enhanced MRI of the entire neuraxis lack both specificity and sensitivity. The Veridex CellSearch® technology has been designed for the detection of circulating tumor cells (CTC) in blood from cancer patients and validated for the follow-up and prognosis of breast, prostate, colorectal, and lung cancer. Our aim was to adapt this technology for the detection and the enumeration of tumor cells in the CSF of breast cancer patients presenting with LM.

METHODS: On the occasion of a randomized phase III study evaluating the role of the intrathecal treatment in LM from breast cancer (DEPOSEIN, EudraCT N°: 2010-023134-23), the CellSearch® technology was adapted to direct enrichment, enumeration and visualization of tumor cells in 5 mL CSF samples, collected on CellSave® Preservative Tubes and analyzed within 3 days after CSF sampling.

RESULTS: Sixteen CSF of 8 patients with primary breast cancer presenting with LM were studied. EpCAM+/cytokeratin + cells with typical morphology could be observed and enumerated sequentially with reproducible results in low or elevated numbers in 8 patients.

CONCLUSION: This methodology, established on a limited volume of sample and allowing delayed processing, could prove of great interest in the diagnosis and follow-up of cancer patients with LM, especially to appreciate the efficacy of chemotherapy.

References

  1. J Neurooncol. 2011 Sep;104(2):565-72 - PubMed
  2. Fluids Barriers CNS. 2011 Mar 03;8(1):14 - PubMed
  3. Clin Cancer Res. 2004 Oct 15;10(20):6897-904 - PubMed
  4. Clin Cancer Res. 2007 Feb 1;13(3):920-8 - PubMed
  5. Cell Prolif. 2006 Dec;39(6):495-505 - PubMed
  6. Oncotarget. 2011 Oct;2(10):752-60 - PubMed
  7. Proteomics. 2007 Feb;7(3):474-81 - PubMed
  8. Clin Chem Lab Med. 2009;47(7):874-9 - PubMed
  9. Arch Neurol. 2010 Mar;67(3):305-12 - PubMed
  10. Ann Oncol. 2010 Nov;21(11):2183-2187 - PubMed
  11. J Neurooncol. 2007 Aug;84(1):57-62 - PubMed
  12. J Neurooncol. 2009 Dec;95(3):421-426 - PubMed
  13. Breast Cancer Res Treat. 2011 Oct;129(3):809-17 - PubMed
  14. Semin Oncol. 2009 Aug;36(4 Suppl 2):S35-45 - PubMed
  15. Cancer. 1998 Feb 15;82(4):733-9 - PubMed
  16. J Neurol Sci. 1994 Jan;121(1):74-8 - PubMed
  17. Neurology. 2011 Jan 11;76(2):200; author reply 200-1 - PubMed
  18. Future Oncol. 2010 Feb;6(2):287-97 - PubMed
  19. Curr Opin Oncol. 2010 Nov;22(6):627-35 - PubMed
  20. J Cancer Res Clin Oncol. 2010 Nov;136(11):1729-35 - PubMed
  21. J Neurooncol. 2009 Sep;94(2):229-34 - PubMed
  22. J Oncol. 2010;2010:617421 - PubMed

Publication Types